These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 18789844

  • 1. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 2. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1810-5. PubMed ID: 18727948
    [Abstract] [Full Text] [Related]

  • 3. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun 12; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 4. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Apr 12; 47(4):472-8. PubMed ID: 23375406
    [Abstract] [Full Text] [Related]

  • 5. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP, Khan A.
    Schizophr Res; 2011 Feb 12; 125(2-3):267-77. PubMed ID: 20850275
    [Abstract] [Full Text] [Related]

  • 6. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
    Chaudhry IB, Husain N, Husain MO, Hallak J, Drake R, Kazmi A, Rahman Ru, Hamirani MM, Kiran T, Mehmood N, Stirling J, Dunn G, Deakin B.
    Trials; 2013 Apr 17; 14():101. PubMed ID: 23782463
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ.
    Schizophr Res; 2006 Dec 17; 88(1-3):102-10. PubMed ID: 16959472
    [Abstract] [Full Text] [Related]

  • 8. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, Noorbala AA, Ahmadi-Abhari SA, Hajiazim M, Abbasi SH, Akhondzadeh S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr 01; 32(3):726-32. PubMed ID: 18096287
    [Abstract] [Full Text] [Related]

  • 9. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec 01; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 10. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.
    CNS Drugs; 2013 Jan 01; 27(1):57-65. PubMed ID: 23233269
    [Abstract] [Full Text] [Related]

  • 11. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS.
    J Clin Psychiatry; 2010 Nov 01; 71(11):1475-81. PubMed ID: 20816042
    [Abstract] [Full Text] [Related]

  • 12. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B.
    Schizophr Res; 2007 Feb 01; 90(1-3):179-85. PubMed ID: 17208413
    [Abstract] [Full Text] [Related]

  • 13. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.
    J Clin Psychopharmacol; 2013 Jun 01; 33(3):336-42. PubMed ID: 23609382
    [Abstract] [Full Text] [Related]

  • 14. Ondansetron - a promising adjunctive treatment for persistent schizophrenia.
    Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Gurvich C.
    J Psychopharmacol; 2018 Nov 01; 32(11):1204-1211. PubMed ID: 30359166
    [Abstract] [Full Text] [Related]

  • 15. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
    Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S.
    Psychopharmacology (Berl); 2013 Aug 01; 228(4):595-602. PubMed ID: 23515583
    [Abstract] [Full Text] [Related]

  • 16. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH, Wang GH, Wang XP, Chen RY, Wang HL, Yang MH, Huo YX, Mei HB.
    Hum Psychopharmacol; 2008 Aug 01; 23(6):465-70. PubMed ID: 18536066
    [Abstract] [Full Text] [Related]

  • 17. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1879-83. PubMed ID: 18801405
    [Abstract] [Full Text] [Related]

  • 18. The role of ondansetron in the treatment of schizophrenia.
    Bennett AC, Vila TM.
    Ann Pharmacother; 2010 Dec 12; 44(7-8):1301-6. PubMed ID: 20516364
    [Abstract] [Full Text] [Related]

  • 19. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.
    Clin Neuropharmacol; 2013 Dec 12; 36(6):185-92. PubMed ID: 24201233
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.
    Hum Psychopharmacol; 2008 Mar 12; 23(2):79-86. PubMed ID: 17972359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.